2021
DOI: 10.1080/1744666x.2021.1945441
|View full text |Cite
|
Sign up to set email alerts
|

Novel biomarkers for prediction of outcome and therapeutic response in juvenile idiopathic arthritis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
13
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 14 publications
(31 citation statements)
references
References 151 publications
0
13
0
Order By: Relevance
“… 1 Early diagnosis and prediction of disease course and therapeutic response are crucial for patient management but are hindered by the lack of biomarkers. Identification of new low‐invasive biomarkers is thus highly required to improve the current diagnosis of OJIA patients and help with the setting up of targeted treatments at disease onset, which would allow to reduce the burden of the disease, limit the occurrence of joint damage and loss of functionality, minimize patient exposure to the potential side‐effects of ineffective medication, and induce earlier remission, thus enhancing patient quality of life 2 (Supporting Information, Section 1). Extracellular vesicles (EVs) released into biologic fluids have gained increased recognition as key mediators of the pathogenesis of many chronic inflammatory and autoimmune diseases, including adult arthritides, 3 and as a reliable and enriched source of disease biomarkers, by virtue of their cargo of bioactive molecules (nucleic acids, proteins, and lipids) of cellular origin, which can be transferred to, and elicit responses in, recipient cells.…”
Section: Figurementioning
confidence: 99%
“… 1 Early diagnosis and prediction of disease course and therapeutic response are crucial for patient management but are hindered by the lack of biomarkers. Identification of new low‐invasive biomarkers is thus highly required to improve the current diagnosis of OJIA patients and help with the setting up of targeted treatments at disease onset, which would allow to reduce the burden of the disease, limit the occurrence of joint damage and loss of functionality, minimize patient exposure to the potential side‐effects of ineffective medication, and induce earlier remission, thus enhancing patient quality of life 2 (Supporting Information, Section 1). Extracellular vesicles (EVs) released into biologic fluids have gained increased recognition as key mediators of the pathogenesis of many chronic inflammatory and autoimmune diseases, including adult arthritides, 3 and as a reliable and enriched source of disease biomarkers, by virtue of their cargo of bioactive molecules (nucleic acids, proteins, and lipids) of cellular origin, which can be transferred to, and elicit responses in, recipient cells.…”
Section: Figurementioning
confidence: 99%
“…In the past two decades, there have been important therapeutic advances in the management of JIA, however, to date, we are not yet able to predict the course of the disease, the therapeutic response, and relapses after drug discontinuation. Therefore, there is a great need for biomarkers to guide clinical decisions such as starting, switching, or tapering methotrexate or biologic DMARDs [ 3 ].…”
Section: Introductionmentioning
confidence: 99%
“…The increased levels of suPAR were predominantly detected in polyarticular JIA but can be a result of few individuals in the other subgroups. Reliable predictive markers of aggressive disease course are important for identifying the individuals in need of more efficacious treatments before irreversible joint destruction occur, but it is also important to avoid treating patients with lower risk [ 9 ]. Although the results indicate that analysis of suPAR could be of additional value in assessing the risk of erosions in JIA, the observations need to be confirmed in prospective studies.…”
Section: Discussionmentioning
confidence: 99%
“…Unfortunately, at the time of diagnosis it is often difficult to predict the future risk for joint erosion and destruction. Since reliable predictive markers are largely lacking, the immunomodulatory treatments are usually introduced stepwise based on the clinical response over time [ 9 , 10 ].…”
Section: Introductionmentioning
confidence: 99%